Bioanalytical Best Practice in Australia a CPR perspective. by Andrew Dinan Senior Director Bioanalytical Services CPR Pharma Services, Australia
|
|
- Peter Boyd
- 5 years ago
- Views:
Transcription
1 Bioanalytical Best Practice in Australia a CPR perspective by Andrew Dinan Senior Director Bioanalytical Services CPR Pharma Services, Australia
2 Outline History of Bioanalysis in Australia CPR Future Setup Case studies Challenges CPR, Adelaide 2
3 1980 s History in Australia 1990 s Bioequivalence (BE) trials in Universities No BMV guidance to follow individual best practise BE studies continued 1st ever BMV workshop in 1990 Sponsored by AAPS, FDA, FIP, HFB, AOAC Harmonised validation and became the benchmark in Australia CMAX opened 1st dedicated Phase 1 site Bioanalytical unit - ISO & GLP Accreditation 3
4 History in Australia 2000 s FIH studies commenced BE studies USA companies attracted by fast Regulatory framework for mainly NCE FIH studies Small NCE Australian market Reduced dramatically through low cost competition India, China. Lead to closure of 2 Bioanalytical units that were part of phase 1 units in Adelaide (CMAX) and Brisbane (Qpharm) 2001 FDA guidance Adopted as BMV standard in Australia CPR, Adelaide 4
5 2010 s History in Australia FIH studies Continue with Global appeal high quality, fast regulatory framework, R&D tax incentive Global Bioanalytical meetings Attend to know acceptable BMV standards that were NOT in regulatory guidances e.g. ISR, matrix effects, etc. WRIB, EBF, AAPS, GBC, GCC 2012 EMA guidance issued Most Bioanalytical work in Australia supports studies for US, European submission. Therefore AAPS 2001, EMA 2012 guidances followed and associated workshops. 5
6 History in Australia 2010 s BMV still not consistently applied across global CROs CPR reviews many Global CRO Tox and Human assays to support FIH studies conducted in Australia Differences in Whole blood, Matrix effects, lipemic, A&P Acceptance criteria, etc 2020 s the Future BMVs USA, European, Japanese, Canadian, etc Global BMV?? (e.g. ICH GMP??) GBC status?? CPR, Adelaide 6
7 CPR A Specialist Early Phase CRO CPR is the only Australian CRO that has a synergistic combination of 1. Clinical and data management services 2. GLP-accredited Bioanalytical laboratory (PK, PD, ADA) Collaborates with all 6 dedicated clinical Phase I sites across Australia and New Zealand Focus on early phase clinical trials e.g. FIH Phase 1 CPR, Adelaide 7
8 CPR - History University of South Australia 1980 s: Originated within School of Pharmacy BE studies 1996: Centre for Pharmaceutical Research formed (CPR) 2005: CPR became commercial - no longer funded by University CPR Pharma Services Pty Ltd 2009: 20 people Spun out from University as a private company 2007 Australian Government grant approval ~$1M, with matching funds raised in : currently ~90 people CPR, Adelaide 8
9 Our Customers CPR s client portfolio Company type Geography Small-medium pharma main customer Biotech - some Large pharma - limited USA (~ 50%) Australia / NZ Asia Pacific India, South Korea, China Europe High Repeat rate > 80% CPR, Adelaide 9
10 GLP Bioanalytical Services Specialist in regulated bioanalysis Quantitate drug &/or metabolite in biological matrices plasma, serum, urine etc. Supports pharmacokinetic (PK) & pharmacodynamic (PD) evaluation required during the drug development process. Analytical platforms LC/MS/MS for small molecules to polypeptides (50AA ~ insulin), oligonucleotides. Immunoassay for larger biologics i.e. MAbs, proteins. 10
11 Quality Systems 2004 ISO Accreditation Appropriate for clinical sample analysis Quality manual, preventative & corrective action, continuous improvement Technical competence verified by external party NATA 2007 GLP Accreditation Strictly for Pre-Clinical studies But also applied to clinical sample analysis, method validation Successful FDA audit QA verified by Large pharma & Global CRO partners Comply with latest USA/EMA BMV Guidances Attend latest global bioanalytical forums WRIB, EBF, JBF 11
12 Regulatory team at work 12
13 LC/MS/MS Analytical Capability LC/MS/MS Sciex 5*4000s, most common in large pharma & CROs 5500 Qtrap High sensitivity if required Steroids, neurotransmitters dermal / inhalation phase 0, low dose, paediatric studies low volume All LC/MS/MS fully qualified and under change control Service contracts and local engineer available same day 13
14 LC/MS/MS Analytical Capability 14
15 LC/MS/MS Expertise and Experience R&D team of senior chemists Conduct complex method development Combine team expertise for: Troubleshooting Deliver assay development under tight deadlines Experience Drug chemistries sugars, nucleotides, enantiomers, steroids, prodrugs, immunosuppressants, neurotransmitters, peptides. Drug conjugates, nanoparticles 15
16 Dihydroartemisin Small molecules All tests pass with fast protein precipitation assay However, haemolysed blood the response decreased for drug by -95% Assay re-developed with solvent extraction where the purity/source of solvent was important Postulated that the drug was reacting with free radicals in haemolysed blood and solvent impurities MOA is within red blood cells makes sense to react with lysed cells Testosterone Testosterone assay developed for 20ul cord serum from newborns Random contamination seen Vital that all surfaces in the assay process are swabbed/cleaned of deposited testosterone from males 16
17 Small Molecules Nanoparticle Nanoparticle designed to release cytotoxic drug in the biological system Cytotoxic load in vast excess to free drug, 100,000 ng/ml equivalent in nanoparticle (Total) ~100 ng/ml free (1,000 fold excess) Stability investigation covering temperature, plasma species, whole blood vs. plasma, chemical inhibitors, ph Solution on ice with acid stabiliser & control time of exposure Stability acceptable and was fully validated NCE Urine stability failed at -20 C, passed at -80 C Investigations uncovered correlation with excessive ph change 17
18 Australian venomous creatures CPR, Adelaide 18
19 Peptides High level Expertise Over a decade of experience (2001 on) with Bioanalysis of intact peptides in plasma 15%, 4/6 criteria small molecule criteria Key Learnings Keeper solution to prevent surface adsorption Solution chemistry optimisation to prevent aggregations e.g. Amyloid beta peptides Weak cation exchange SPE for Arginine containing peptides Optimise Resolution settings Good IS analog or SIL Shallow gradients and high column temperature Examples fully validated Glucagon, Vessel Dilator Various NCE peptides 19
20 Oligonucleotides New areas Pure standard technical feasibilities conducted for clients: Antisense strand - ~5kDa Theoretical LLOQ 1ng/ml SiRNA ~ 15kDa Theoretical LLOQ 10ng/ml Current 6 month project with University of South Australia Bioanalysis of oligos Protein MS Tryptic digest for signature peptide Also assessing very large peptides for intact analysis 70 AA s e.g. IGF-1. 20
21 Immunoassay/Ligand Binding Services Quantitative PK analysis of macromolecules, including monoclonals Biomarkers Immunogenicity (anti-drug assays) Neutralising antibody assays Reagent labelling and affinity purification Fully GLP Compliant 21
22 What We Measure: Molecule Type Recombinant Proteins Monoclonal Antibodies Oligonucleotides Fusion Proteins Biosimilars Bioanalytical Services Supporting Drug Development in Australia 22
23 Australia s Contribution to Biosimilar Validation First Consensus White Paper on Assay Validation Requirements. Bioanalytical Services Supporting Drug Development in Australia 23
24 Immunoassay Case Study Project: Validation of PK and ADA Assays for a Monoclonal Antibody for a small Biotech company. Drug is a Pentameric IgM Molecule. Assay performed on the MSD system. Client has worked with a global CRO who had performed over 150 runs of method development and still could not get the assay to perform. Clinical Trial in complex Disease interference matrix. Global CRO had been working on the assay for 12 months. Interferences solved using some novel techniques. CPR started work and completed the Method Development and Method Validation within 3 months. Sample Analysis completed and met the timelines set by the client. With client s permission data is to be published in poster format. Presented with client s permission, November 2014 Bioanalytical Services Supporting Drug Development in Australia 24
25 Immunoassay Case Study (contd.) Bioanalytical Services Supporting Drug Development in Australia 25
26 Summary Early phase clinical trial specialists, offering clinical and bioanalytical services, as individual components or a full service Track record of quality and timely delivery (with high repeat business) CPR Pharma Services, Australia : integrated solution for the Asia-Pacific region CPR, Adelaide 26
27 Future Bioanalysis A-Pac Past to Present 1st Asia-Pacific Bioanalytical Workshop China 6 th Japanese Bioanalytical Forum (JBF) Started nd China Bioanalytical Forum (CBF) Started 2013 Future??? 2nd Asia-Pacific Bioanalytical Workshop??? Expert presentations science, regulatory Training courses and workshops for the regions workers of the future! In Australia...All Welcome!! CPR, Adelaide 27
28 Thank You! Thank you for your kind invitation to present today!! South Australia CPR, Adelaide 28
Your bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationBioanalytical sciences Helping you get the most from your precious samples
accuracy regulatory testing chemical measurement bioanalysis standards GLP GCP cgmp LGC in drug development Bioanalytical sciences Helping you get the most from your precious samples analytical quality
More informationLAB EXPERTS AT YOUR SIDE Over twenty years of experience
LAB EXPERTS AT YOUR SIDE Over twenty years of experience About us SYNLAB Pharma offers a broad range of laboratory services to the biotechnology, pharmaceutical and cosmetic industries as well as to manufacturers
More informationEuropean Bioanalysis Forum
European Bioanalysis Forum Alternative Approaches for Assessment of Drug Neutralizing Activity of ADA Responses Presenter: Arjen Companjen (on behalf of EBF topic team 19) EIP meeting Lisbon 25 February
More informationSuccessful transfer of ligand binding assays between different laboratories
Successful transfer of ligand binding assays between different laboratories Debbie McManus Team Leader, Department of Biomarkers, Bioanalysis and Clinical Sciences 10 th EBF Open Symposium Hesperia Tower,
More informationSpecific Presentations and Discussion Topics for The 1 st CRO Closed Forum (Montreal, Sept. 14 th 2010)
Specific Presentations and Discussion Topics for The 1 st CRO Closed Forum (Montreal, Sept. 14 th 2010) Advion Interfacing with the FDA on issued 483 s an Opportunity to Discuss Science and Address Misunderstandings?
More informationCase Studies on ultra-sensitive immunoanalytics based on Imperacer (Immuno-PCR) in clinical settings. Jan Detmers, Ph.D. (Chimera Biotec GmbH)
Case Studies on ultra-sensitive immunoanalytics based on Imperacer (Immuno-PCR) in clinical settings. Jan Detmers, Ph.D. (Chimera Biotec GmbH) Agenda 1.Overview Platforms 2.Immuno-PCR (Imperacer ) Technology
More information6 th EBF Open meeting, Barcelona November 21st, 2013
Validation of an immunoassay to selectively quantify the naked antibody of a new Sanofi Antibody Drug Conjugate: an additional tool for improvement of PK interpretation 6 th EBF Open meeting, Barcelona
More informationSubmission preparation what to watch out for
Submission preparation what to watch out for EBF 2017 Boris Gorovits AAPS BIOTEC section Pfizer June 2017 Analytes Commonly Assessed for ADC PK Unconjugated Drug analyte Total Antibody analyte Conjugated
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationBioanalysis of peptides and proteins in drug research and development: from strategy into practice.
Bioanalysis of peptides and proteins in drug research and development: from strategy into practice. Lieve Dillen Drug Safety Sciences Analytical Sciences, n-regulated Bioanalysis Presentation outline Some
More informationENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY
BIOANALYTICAL SOLUTIONS FOR BIOTHERAPEUTICS AND SMALL MOLECULE THERAPEUTICS ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY MARCH 15, 2017 AIT BIOSCIENCE, LLC BIOANALYSIS TO SUPPORT
More informationCurrent Trends in GLP-like Analysis
Current Trends in GLP-like Analysis CORESTA Biomarker Sub-Group Kirk Newland - Celerion Sources of Insight into Regulatory Requirements Guidance Harmonization Recent published discussions between the FDA,
More informationLigand Binding Assays: Summary and Consensus from the Bioanalytical Workshop (CC V)
Ligand Binding Assays: Summary and Consensus from the Bioanalytical Workshop (CC V) Binodh DeSilva Executive Director Immunochemistry and Biomarker Development Bristol-Myers Squibb Contributors Lauren
More informationPPD LABORATORIES COMPREHENSIVE SERVICES
PPD LABORATORIES COMPREHENSIVE SERVICES PPD_Comprehensive_Brochure2016_SinglePages_FINAL.indd 1 6/9/2016 6:04:02 PM PPD LABORATORIES: GLOBAL INNOVATIVE PROVEN PPD Laboratories combines world-class scientific
More informationDevelopment of an Immunoprecipitation and LC-MS/MS based Method for Quantifying the 105 kda Recombinant Protein SXN in Plasma.
Development of an Immunoprecipitation and LC-MS/MS based Method for Quantifying the 105 kda Recombinant Protein SXN101959 in Plasma. Richard Kay Principal Scientist, Bioanalytical Sciences, Quotient Bioresearch
More informationPHARMACEUTICAL BIOANALYSIS BIOANALYSIS SERVICES. Bioanalytical Expertise for Large and Small Molecules
PHARMACEUTICAL BIOANALYSIS BIOANALYSIS SERVICES Bioanalytical Expertise for Large and Small Molecules Our Bioanalytical Expertise Bioanalysis plays a critical role in the assessment of drug safety and
More informationAffigenix Biosolutions Private Ltd, 265/ 1F, KSSIDC Industrial Area Bangalore, Karnataka,India
Host Cell Protein & Other Impurity Clearance Assays for Biosimilar Development Omics Biowaivers, Biologics & Biosimilars- Oct 29, 2014 Affigenix Biosolutions Private Ltd, 265/ 1F, KSSIDC Industrial Area
More informationPharmacokinetic Analysis of the mab Adalimumab by ELISA and Hybrid LBA/LC/MS: A Comparison Study
Pharmacokinetic Analysis of the mab Adalimumab by ELISA and Hybrid LBA/LC/MS: A Comparison Study Featuring the SCIEX BioBA Solution Xi Qu 1, Shuyu Hou 1, Meghan McCann 1, Caroline Becker 1, Xun Wang 1,
More informationChapter 2 Understanding Bioanalysis Regulations
Chapter 2 Understanding Bioanalysis Regulations Mark Arnold, Eric Fluhler and Boris Gorovits Abstract Bioanalytical data submitted to global health authorities in support of drug approval applications
More informationScience. Enhancing the Pharma-CRO relationship with a focus on method transfer. for a safer world
Enhancing the Pharma-CRO relationship with a focus on method transfer Chris Jones, Client Manager, Drug Development Services, LGC EBF Open Symposium, 18 th November 2015 Science for a safer world Overview
More informationHARMONIZATION TEAM A6 (STABILITY) UPDATE. Yoshiaki Ohtsu 8 March 2012
HARMONIZATION TEAM A6 (STABILITY) UPDATE Yoshiaki Ohtsu 8 March 2012 Contents 1. General update 2. Scientific discussion point 1. Stability of presence of co administered or co formulated drugs 2. Incurred
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationQUESTIONS AND ANSWERS TO ICH S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES FOCUS ON MICROSAMPLING
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE QUESTIONS AND ANSWERS TO ICH S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationIntertek Melbourn Company Presentation. MIBio 2016
Intertek Melbourn Company Presentation MIBio 2016 November 2016 Global Leader in quality solutions across all industries Innovative and bespoke quality solutions for our clients 24/7 FTSE 100 company in
More informationGuideline/Guidance Comparison on Ligand Binding Assays (LBA)
http://bioanalysisforum.jp/ Guideline/Guidance Comparison on Ligand Binding Assays (LBA) vs EMA Guideline (2011, updated 2014) vs Scope This guideline is applicable to the validation of LBAs as analytical
More informationGuideline/Guidance Comparison on Ligand Binding Assays (LBA)
Guideline/Guidance Comparison on Ligand Binding Assays (LBA) vs EMA Guideline (2011, updated 2014) vs Scope This guideline is applicable to the validation of LBAs as analytical methods for the measurement
More informationConsiderations for Successful Biomarker Bioanalysis in Regulated Environment
Considerations for Successful Biomarker Bioanalysis in Regulated Environment Darshana Jani, M.Sc. Darshana.Jani@pfizer.com 10 th European Bioanalysis Forum November 15, 2017 1 Disclaimer The contents of
More informationApplying Affimers. Dr Amanda Nicholl at Avacta Life Sciences. Improving Antibody PK Assay Development
Improving Pharmacokinetic Assays in a Regulatory Bioanalysis Setting Applying Affimers With an increasing number of antibody-based therapeutics entering the clinic, the need for validated anti-idiotypic
More informationUpdate on the new immunogenicity guideline in the EU
Update on the new immunogenicity guideline in the EU draft 2016 EBF, Lisbon 27 th September 2016 Venke Skibeli, Senior Scientist, PhD Norwegian Medicines Agency, Member of the CHMP - BMWP, EMA, London
More informationRisk-based testing for anti-drug neutralizing antibodies during development of biological therapeutics
Risk-based testing for anti-drug neutralizing antibodies during development of biological therapeutics April 18 th, 2016 AAPS National Biotechnology Conference, Boston, MA Shalini Gupta, PhD Amgen Inc.
More informationAT A GLANCE. inventivhealthclinical.com
AT A GLANCE inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 PHASE I-IIA 03 PHASE IIB-III 04 LATE STAGE 05 STRATEGIC RESOURCING 06 BIOANALYTICAL 07 QUALITY ASSURANCE 08 CONSULTING 09 THERAPEUTIC
More informationUsing Ligang-Binding Assay Sensitivity for Improved Matrix Tolerance and Related Parameters by Tailored Sample Dilution.
Using Ligang-Binding Assay Sensitivity for Improved Matrix Tolerance and Related Parameters by Tailored Sample Dilution. Dr. Mark Spengler, Chimera Biotec Chimera Biotec Company Overview Bioanalytical
More informationStrategies to Improve Drug Tolerance in Nab Assays
Strategies to Improve Drug Tolerance in Nab Assays Steven J Swanson, PhD Senior Vice President, Research ImmunoCellular Therapeutics Ltd steven.swanson@imuc.com AAPS National Biotech Conference June 2015
More informationWhat s the difference? Challenges in pre-clinical development of biologics
Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31
More informationImmunogenicity. How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit
Immunogenicity How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit Club Phase I, 22 March 2016 1 Outline Introduction to immunogenicity Analytical challenges for immunogenicity
More informationS3A:Note for guidance on toxicokinetics: The assessment of systemic exposure in toxicity studies. Q&A: FOCUS ON MICROSAMPLING
S3A:Note for guidance on toxicokinetics: The assessment of systemic exposure in toxicity studies. Q&A: FOCUS ON MICROSAMPLING (Step 2b draft) International Council for Harmonisation of Technical Requirements
More informationABOUT KYMOS. Our commitments. Quality assurance. Location
Animal Health ABOUT KYMOS Kymos is a CRO that provides high quality analytical services in small molecule and biologic fields for diferent industries: Biotechnology Pharma Veterinary Phytopharma Nutraceuticals
More informationRegulatory Reflections on the BMV Guideline/Guidance Harmonization
Regulatory Reflections on the BMV Guideline/Guidance Harmonization EBF - Focus Workshop: Industry input into ICH M10 September 25-27, 2014, Noriko Katori, PhD National Institute of Health Sciences, Japan
More informationOverview Stability testing is an essential part of drug development which ensures the quality, safety and efficacy of the drug for the lifetime of the drug product. Appropriate storage conditions can only
More informationCurrent practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim
Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim S Blech EBF Focus Workshop: Metabolite Profiling and Quantification Strategies in Drug R&D Sep 25,
More informationADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW
ADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW Johannes Stanta PhD Scientific Manager, Bioanalysis EBF ADC Training day June 2017 Copyright 2017 Covance. All Rights Reserved ADC Bioanalytical PK Assays
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationOptimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances
Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances Jian Wang, MD, PhD Chief, Clinical Evaluation Division Biologics and Genetic Therapies Directorate Health
More informationBioanalytical Support to In Vitro Studies
Bioanalytical Support to In Vitro Studies Presenter: Tim Sangster (on behalf of EBF (mini-workshop)) Open Symposium 2017 November 17 th 2017 Barcelona http://www.europeanbioanalysisforum.eu Agenda Ø Scope
More informationCritical reagents in LBA
Critical reagents in LBA Presenter: Susanne Pihl on behalf of the EBF Focus Workshop (In collaboration with the AAPS and JBF) Industry input into ICH M10: Experimental data as the cornerstone for a science
More informationOutcomes of the Global Bioanalysis Consortium s Recommendations: Large Molecule Discussion Topics. Binodh DeSilva on behalf of LM Harmonization Teams
Outcomes of the Global Bioanalysis Consortium s Recommendations: Large Molecule Discussion Topics Binodh DeSilva on behalf of LM Harmonization Teams TEAM LEADS TEAM Team Lead L1 Specific run Acceptance
More informationBioanalytical LC-MS of monoclonal antibody therapeutics
Bioanalytical LC-MS of monoclonal antibody therapeutics William D van Dongen, product manager pharma bioanalysis small molecules immunogenicity 40 years experience in bioanalysis Bioanalytical Expertise
More informationGuideline/guidance Comparison on Large Molecule Bioanalysis
Guideline/guidance Comparison on Large Molecule Bioanalysis 6th JBF Symposium 2014.2.26 Jun Hosogi Kyowa Hakko Kirin Co.,Ltd. MHLW/EMA/FDA BMV guidelines (LBA section) MHLW (LBA) 2014 EMA (7. LBA) 2011
More informationSchool of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
More informationEBF Recommendation for Stability Testing of Anti-Drug Antibodies; Lessons Learned from Anti-Vaccine Antibody Stability Studies
EBF Recommendation for Stability Testing of Anti-Drug Antibodies; Lessons Learned from Anti-Vaccine Antibody Stability Studies Presenter: Janka Ryding Presentation based on publication: Pihl S, Michaut
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationQualifying SPR immunogenicity assays Dr. Christian Kühne
Qualifying SPR immunogenicity assays Dr. Christian Kühne Bioagilytix / IPM Biotech global CRO for large molecule bioanalysis supporting pre-clinical & clinical studies Biomarker, Pharmacokinetics, Immunogenicity
More informationNDA Advisory Services Ltd
Declaration of Interest statement: Paul Chamberlain has received Consulting fees from different companies in respect of strategic and operational advice relating to biopharmaceutical development; he is
More information3M Drug Delivery Systems. April 26, 2011
3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationNUVISAN GROUP. Our Philosophy
NUVISAN GROUP Our Philosophy 2 EARLY DEVELOPMENT Introduction to Nuvisan Fully integrated Contract Research Organisation headquarted in Neu-Ulm, southern part of Germany. Nuvisan - Early Development Headquartered
More informationABF Pharmaceutical Services GmbH
ABF Pharmaceutical Services GmbH Facts and Figures GBA is a European laboratory group with an annual turnover of +40 M. Founded in 1989, Hamburg Our business covers Pharma, Environmental, Foodstuff, Consumer
More informationICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers
14 December EMA/CHMP/ICH/320985/2016 Committee for Medicinal Products for Human Use ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationDevelopment of an ELISA for the measurement of TNF-alpha in clinical samples
Development of an ELISA for the measurement of TNF-alpha in clinical samples Liz Hickford, Senior Scientist, Bioanalytical Sciences, UCB EBF Young Scientist Symposium 17.NOV.15 Agenda TNF-alpha as a clinical
More informationBiochromatography Bring more Zen into your life and laboratory
Seminar Biochromatography Bring more Zen into your life and laboratory Method development and maintaining peptide, protein, glycan and anti-body analyses by LC or LC-MS can be very time consuming and might
More informationMethod Validation Studies How GLP Interacts With Guidance Documents
Method Validation Studies How GLP Interacts With Guidance Documents Steven S. Kuwahara ROBERT GEORGE YOUNG/GETTY IMAGES GLP Forum addresses topics of interest associated with good laboratory practices.
More informationGary A. Schultz, Advion BioServices, Inc. Ithaca, NY 14850
Validation of an immunoprecipitation, digestion and immunoaffinity LC/LC/nanoLC-MS/MS assay for human b-nerve growth factor (NGF) and implementation in support of clinical trials Gary A. Schultz, schultzg@advion.com
More informationLECTURE 8. Biologics and Future Technologies for the Clinical Laboratory
LECTURE 8 Biologics and Future Technologies for the Clinical Laboratory Jack Henion Quintiles Bioanalytical and ADME Labs Lecture 8, Page 1 New and Developing LC/MS Bioanalytical Capabilities: A Representative
More informationCurrent Best Practices in Commercial Kit Evaluation and Validation for Biomarker Assays
Current Best Practices in Commercial Kit Evaluation and Validation for Biomarker Assays 10th Workshop on Recent Issues in Bioanalysis, 2016 Paul Rhyne, Ph.D. - Director of Immunoassay Services Copyright
More informationSmall molecule bioanalytical method development and transfer: is a plug and play approach possible?
Small molecule bioanalytical method development and transfer: is a plug and play approach possible? Luca Ferrari Clinical Pharmacology and Bioanalytical R&D, pred Pharmaceutical Sciences, Roche Innovation
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of
More informationRevised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion
Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion Robin Thorpe & Meenu Wadhwa Revised Guideline: Differences from original
More informationSHORT COURSE. Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SUNDAY, SEPTEMBER 17
SHORT COURSE SUNDAY, SEPTEMBER 17 OMNI PROVIDENCE HOTEL PROVIDENCE, RI Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SPONSORED BY: Organized by: www.bostonsociety.org
More informationChanges Impacting Bioequivalence Inspections: What s New?
Changes Impacting Bioequivalence Inspections: What s New? Sam H. Haidar, Ph.D., R.Ph. Division of Generic Drug Bioequivalence Evaluation Office of Study Integrity and Surveillance Center for Drug Evaluation
More informationThe new innovations of mab biolimilars and antibody therapeutics Our dedication to human health
Prestige The new innovations of mab biolimilars and antibody therapeutics Our dedication to human health New Biosimilar Development A Frontier in Biopharmaceuticals Antibody Therapeutics Development Prestige
More informationChallenges for Flow Cytometry in Regulated Bioanalysis
Challenges for Flow Cytometry in Regulated Bioanalysis Minesh Patel Merck Millipore Discovery & Development Solutions. Oxford, UK. Overview Flow cytometry principles Current uses and regulatory environments
More informationThe Best Companion! KOREA MEDICINE RESEARCH INSTITUTE - CRO Based on Reliability and Promise, KMRI will accompany you
www.kmri.co.kr The Best Companion! KOREA MEDICINE RESEARCH INSTITUTE - CRO Based on Reliability and Promise, KMRI will accompany you Introduction The field of life science now is estimated to be important
More information21st Annual International Conference on Drug-Drug Interactions. Zach Mitts Northwest Account Manager
21st Annual International Conference on Drug-Drug Interactions Zach Mitts Northwest Account Manager How memorable can a 5-minute presentation be? COMPANY HISTORY From the work of our Founder, Dr. Andrew
More informationBioBA High Capacity Enrichment Sample Preparation Kit:
BioBA High Capacity Enrichment Sample Preparation Kit: Biologics Bioanalysis Made Easy Ian Moore 1, Chang Liu 1, Gary Impey 1, Suma Ramagiri 1 1 Sciex, Concord, Canada Common Immunocapture Sample Extraction
More informationA Hybrid LBA-QPCR Technique (Proseek ) for Improved Assay Sensitivity. Karen Dowers
A Hybrid LBA-QPCR Technique (Proseek ) for Improved Assay Sensitivity Karen Dowers Outline The need for microsampling Microsampling technique Proseek Problems Associated with Sampling Require relatively
More informationCombination Drug Applications: Nonclinical Reviewer Perspectives. Jessica J. Hawes, Ph.D.
Combination Drug Applications: Nonclinical Reviewer Perspectives Jessica J. Hawes, Ph.D. Disclaimer The opinions expressed in this presentation are solely my own and do not reflect those of the FDA, nor
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationEARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS
EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS As a full service contract research organisation performing phase I to IV clinical trials across Europe and the Americas for 40
More informationImmunogenicity Assessment - Challenges and Strategies
Immunogenicity Assessment - Challenges and Strategies 17Nov2015 Manju Saxena, Ph.D. Scientific Director Intertek Pharmaceutical Services 1 Presentation Outline Introduction Immunogenicity Testing (ADA
More informationIncreased Sensitivity through GC- MS/MS
Introducing InVentiv Health Clinical Important Impact of GLP Certification Dr. Jim Settlage joins our team Success Story & Client Testimonial New Technology for Improved Quantitation and Sensitivity Increased
More informationICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers
1 2 3 13 May EMA/CHMP/ICH/320985/ Committee for Human Medicinal Products 4 5 6 7 ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationSpecialty Lab Services. Deep science at scale
Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationBackground. Ferring Pharmaceuticals
Background Ferring Pharmaceuticals Founded in 195 and have since then worked with peptides Today, focus are on peptides as well as proteins Many of our peptides are agonists targeting the oxytocin or vasopressin
More informationPLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS
PLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS Louise Angell Lead Scientist 10th Biosimilars & Follow-On Biologics Congregation 9 th May 2017 Copyright @ 2017 Covance. All rights Reserved Overview
More informationTHE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences
THE INNOVATION COMPANY HEALTH Institute for Biomedicine and Health Sciences Our central activity is innovative applied research that bridges the gap between basic research and industrial applications.
More informationEBF view and future perspective of free/total large molecule drug quantification
EBF view and future perspective of free/total large molecule drug quantification Roland Staack on behalf of the European Bioanalysis Forum (EBF) 9th JBF Symposium February 6-8, 2018 Tokyo http://www.europeanbioanalysisforum.eu
More informationImmunogenicity of Biological products
Immunogenicity of Biological products Pierre Cortez Sanofi-aventis Metabolism and Pharmacokinetic Department, Lyon / April 28, 2009 Agenda Introduction Immunogenicity monitoring Guidelines, white papers
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationCERTIFICATE IN BIOPHARMACEUTICALS
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN BIOPHARMACEUTICALS and GENERIC DRUGS Temple offers
More informationChromatography column for therapeutic protein analysis
PRODUCT SPECIFICATIONS ProPac Elite WCX Column Chromatography column for therapeutic protein analysis Benefits Superior resolution power for proteins, monoclonal antibodies, and associated charge variants
More informationIntertek Pharmaceutical Services Laboratory & Assurance Solutions. Pharmaceutical Services
Intertek Pharmaceutical Services Laboratory & Assurance Solutions Pharmaceutical Services Across your product lifecycle, our expertise brings you the insight you need to accelerate pharmaceutical, biopharmaceutical
More informationImproving Sensitivity for an Immunocapture LC-MS Assay of Infliximab in Rat Plasma Using Trap-and-Elute MicroLC-MS
Improving Sensitivity for an Immunocapture LC-MS Assay of in Rat Plasma Using Trap-and-Elute MicroLC-MS Using the SCIEX M3 MicroLC system for Increased Sensitivity in Antibody Quantitation Remco van Soest
More informationPrecipitation and Acid (PandA) to Resolve the Drug and Target Interference Problems in Immunogenicity Assays
Precipitation and Acid (PandA) to Resolve the Drug and Target Interference Problems in Immunogenicity Assays Jad Zoghbi Senior Scientist Boston BCB, Sanofi, Framingham, MA Introduction Circulating therapeutic
More informationSHANGHAI MEDICILON INC.
美迪西生物医药 Integrated Preclinical Drug Discovery Services SHANGHAI MEDICILON INC. Company Profile Shanghai Medicilon Inc. is one of the top contract research organizations (CRO) in China. Since its establishment
More informationQA Production Material and Analytical Methods. BIT 230 Chapters 5 and 6 (Huxsoll)
QA Production Material and Analytical Methods BIT 230 Chapters 5 and 6 (Huxsoll) Material Selection Original qualification of material - vendor, specifications, safety, function, etc. Lot-to-lot testing
More information